http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
선정화,김희택,배성렬,강신춘 한양대학교 에너지·환경기술연구소 1994 에너지·環境技術論文集 Vol.1 No.-
도시지역에서 배출되는 일반폐기물에 대한 성분분석결과 밀도는 250∼300㎏/㎥, 수분함량은 중량비로 평균 51.83%, 가연성분 42.09%, 회분 6.08%로 각각 측정되었다. 한편, 저위발열량은 주거지역이 700∼1,700㎉/㎏, 상업지역이 2,000㎉/㎏이상으로 측정되어 상업지역이 주거 지역보다 발열량이 높은 폐기물이 배출됨을 알 수 있었는데 이는 수분함량이 높은 주개류의 배출이 상업지역이 주거지역보다 적으며 소비자 포장지로서 종이, 비닐, 플라스틱류 등의 사용이 많은데 기인하는 것으로 생각되어 진다. 한편, 분리수거, 유가품에 대한 자원 재활용, 연탄재 배출의 감소추세 등의 효과로 폐기물 중 불연성 함량은 줄어들고 반면 종이, 비닐, 플라스틱류 등의 가연성 폐기물의 함량은 크게 늘어 전체적으로 폐기물의 질이 향상되고 있음을 알 수 있다. The analysis results of components of municipal solid wastes are as follows : ① Density ranged from 250㎏/㎥ to 300㎏/㎥. ② Water content, combustible content and ash content measured 51.83%, 42.09%, 6.08% respectively. ③ Low calorific value was ranged from 700 to 1,700㎉/㎏ in residential area and measured 2,000㎉/㎏ in commercial one. Therefore, it was known that calorific value of wastes in residential area is smaller than that in commercial area. Also, the quality of wastes was improved by increase of combustible content which results from vitality of valuable recycling, reduction trend of briquette ash generation rate and increase of paper, plastic consumption as wrapping materials.
Cathodoluminescence Enhancement of CaTiO<sub>3</sub>:Pr<sup>3+</sup> by Ga Addition
Kang, Seung-Youl,Byun, Jung-Woo,Kim, Jin-Young,Suh, Kyung-Soo,Kang, Seong-Gu Korean Chemical Society 2003 Bulletin of the Korean Chemical Society Vol.24 No.5
The phosphor $CaTiO_3:Pr^{3+}$ attracts much attention as a low-voltage red phosphor because of its good chromaticity and intrinsic conductivity. The addition of Ga into this CaTiO₃:Pr led the luminance intensity to greatly enhance without the change of the wavelength for the electronic transition and the peak shape of it. The increase of the recombination rate of electron-hole pairs through the Ga ion doping, which was expected to play a role of a hole-trap center, is proposed to be one of the reasons for the enhancement of the cathodoluminescence intensity.
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, Mi Ran,Kim, Min Sung,Oh, Ji Eun,Kim, Yoo Ri,Song, Sang Yong,Seo, Seong Il,Lee, Ji Youl,Yoo, Nam Jin,Lee, Sug Hyung Wiley Subscription Services, Inc., A Wiley Company 2009 International journal of cancer: Journal internati Vol.125 No.2
<P>Missense somatic mutations in IDH1 gene affecting codon 132 have recently been reported in glioblastoma multiforme (GBM) and other gliomas. The recurrent nature of the IDH1 mutations in the same amino acid strongly suggests that the mutations may play important roles in the pathogenesis of glial tumors. The aim of this study was to see whether the IDH1 codon 132 mutations occur in other human cancers besides glial tumors. We also attempted to confirm the occurrence of the IDH1 mutations in GBM of Korean patients. We have analyzed 1,186 cancer tissues from various origins, including carcinomas from breast, colon, lung, stomach, esophagus, liver, prostate, urinary bladder, ovary, uterine cervix, skin and kidney, and malignant mesotheliomas, primary GBM, malignant meningiomas, multiple myelomas and acute leukemias by single-strand conformation polymorphism analysis. We found four IDH1 codon 132 mutations in the GBM (4/25; 16.0%), two in the prostate carcinomas (2/75; 2.7%) and one in the B-acute lymphoblastic leukemias (B-ALL) (1/60; 1.7%), but none in other cancers. The IDH1 mutations consisted of five p.R132H and two p.R132C mutations. The data indicate that IDH1 codon 132 mutations occur not only in GBM, but also in prostate cancers and B-ALL. This study suggests that despite the infrequent incidence of the IDH1 mutations in prostate cancers and B-ALL, mutated IDH1 could be therapeutically targeted in these cancers and in glial tumors with the IDH1 mutations. © 2009 UICC</P>
Kang, Woo Youl,Seong, Sook Jin,Ohk, Boram,Gwon, Mi-Ri,Kim, Bo Kyung,La, Sookie,Kim, Hyun-Ju,Cho, Seungil,Yoon, Young-Ran,Yang, Dong Heon,Lee, Hae Won Dove Medical Press 2018 Drug design, development and therapy Vol.12 No.-
<P><B>Purpose</B></P><P>A new fixed-dose combination (FDC) formulation of telmisartan 80 mg and S-amlodipine 5 mg (CKD-828) has been developed to increase convenience (as only one tablet is required per day) and improve treatment compliance.</P><P><B>Methods</B></P><P>The pharmacokinetic characteristics and tolerability of an FDC of telmisartan and S-amlodipine were compared to those after coadministration of the individual agents in this randomized, open-label, single-dose, two-way, four-period, crossover study. To analyze the telmisartan and S-amlodipine plasma concentrations using a validated liquid chromatography–tandem mass spectrometry method, serial blood samples were collected up to 48 hours post-dose for telmisartan and 144 hours post-dose for S-amlodipine, in each period.</P><P><B>Results</B></P><P>Forty-eight healthy subjects were enrolled, and 43 completed the study. The mean peak plasma concentration (C<SUB>max</SUB>) and the area under the plasma concentration–time curve from time 0 to the last measurement (AUC<SUB>0–t</SUB>) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively. The mean C<SUB>max</SUB> and AUC<SUB>0–t</SUB> values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively. The geometric mean ratio (GMR) and 90% confidence interval (CI) for the telmisartan C<SUB>max</SUB> and AUC<SUB>0–t</SUB> (FDC of telmisartan and S-amlodipine/concomitant administration) were 0.8509 (0.7353–0.9846) and 0.9431 (0.8698–1.0226), respectively. The GMR and 90% CI for the S-amlodipine C<SUB>max</SUB> and AUC<SUB>0–t</SUB> (FDC/concomitant administration) were 0.9829 (0.9143–1.0567) and 0.9632 (0.8798–1.0546), respectively. As the intrasubject variability of the C<SUB>max</SUB> for telmisartan administered individually was 42.94%, all 90% CIs of the GMRs fell within the predetermined acceptance range. Both treatments were well tolerated in this study.</P><P><B>Conclusion</B></P><P>CKD-828 FDC tablets were shown to be bioequivalent to coadministration of the individual agents with the respective strength, in healthy subjects under fasting conditions. There was no significant difference in safety profile between the two treatments.</P>
수술로 확인한 갑상선결절의 분류 및 미세침흡인세포검사의 유용성
강성준,김효열,김현만,강남규,김수경 대한내분비학회 1993 Endocrinology and metabolism Vol.8 No.3
The utility of fine needle aspiration (FNA) in the diagnosis of thyroid nodules was assessed in 569 thyroidectomized patients among total 765 cases with thyroid nodules. The available results of FNA biopsy obtained from 430 cases with thyroid nodules revealed benign lesions in 69.5%, follicular lesions in 21.4% and malignant lesions in 9.1%. The pathological classification of 282 thyroidectomized patients with preoperative FNA results (group 1) was compared to that of 287 thyroidectomized patients with none of preoperative FNA results (group 2). The group 1 and group 2 showed similar proportion of pathologic classification: malignant nodules were 23.8%, 20.9%, respectively, adenomatous hyperplasia 57.8%, both, and follicular adenoma 16.3%, 18.8%, respectively. In 67 patients with malignant thyroid diseases, preopeative FNA cytologic diagnosis were malignancy In 28 cases (41.8%), follicular neoplasm in 14 cases, and benign in 25 cases. Sensitivity and specificity of FNA biopsy were 52.8% and 97.9%, respectively. The false negative rate of FNA biopsy was 13.0%. In conclusion, although malignant findings in FNA can be helpful information for the treatment fo thyroid nodules, further diagnostic tests or surgical consideration should not be restricted if FNA showed benign findings(J Kor Soc Endocrinol 8:318~325, 1993).
Kang, Woo Youl,Seong, Sook Jin,Ohk, Boram,Gwon, Mi-Ri,Kim, Bo Kyung,Cho, Seungil,Shim, Wang-Seob,Lee, Kyung-Tae,Kim, Eun Hee,Yang, Dong Heon,Lee, Hae Won,Yoon, Young-Ran Dove Medical Press 2018 Drug design, development and therapy Vol.12 No.-
<P><B>Purpose</B></P><P>A new fixed-dose combination (FDC) formulation of 120 mg fimasartan and 20 mg rosuvastatin was developed to increase therapeutic convenience and improve treatment compliance.</P><P><B>Methods</B></P><P>A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 7-day washout period was conducted to compare the pharmacokinetic (PK) characteristics and bioequivalence between an FDC of fimasartan/rosuvastatin and the separate co-administration of fimasartan and rosuvastatin in healthy Korean volunteers. The plasma concentrations of fimasartan and rosuvastatin were analyzed by a validated liquid chromatography-tandem mass spectrometry method, for which serial blood samples were collected for up to 48 hours post-administration of fimasartan and 72 hours post-administration of rosuvastatin, in each period. The PK parameters were calculated using a non-compartmental method.</P><P><B>Results</B></P><P>A total of 78 subjects completed the study. All the 90% CIs of the geometric mean ratios (GMRs) fell within the predetermined acceptance range. The GMR and 90% CI for the area under the plasma concentration-time curve from time 0 to the last measurement (AUC<SUB>0–t</SUB>) and the maximum plasma concentration (C<SUB>max</SUB>) for fimasartan were 0.9999 (0.9391–1.0646) and 1.0399 (0.8665–1.2479), respectively. The GMR and 90% CI for the AUC<SUB>0–t</SUB> and C<SUB>max</SUB> for rosuvastatin were 1.0075 (0.9468–1.0722) and 1.0856 (0.9944–1.1852), respectively. Treatment with fimasartan and rosuvastatin was generally well tolerated without serious adverse events.</P><P><B>Conclusion</B></P><P>The new FDC formulation of 120 mg fimasartan and 20 mg rosuvastatin can be substituted for the separate co-administration of fimasartan and rosuvastatin, for the advantage of better compliance with convenient therapeutic administration.</P>
Kang, Ji Hye,Lee, Seong Youl,Ahn, Hye Mi,Kim, Cheal Elsevier 2017 Sensors and actuators. B Chemical Vol.242 No.-
<P><B>Abstract</B></P> <P>A new colorimetric chemosensor <B>1</B> for the sequential detection of Ni<SUP>2+</SUP> and CN<SUP>−</SUP> was designed and synthesized. The presence of Ni<SUP>2+</SUP> led to a distinct naked-eye color change from colorless to yellow in a near-perfect aqueous solution. To examine the binding mechanism of <B>1</B> with Ni<SUP>2+</SUP>, UV3–vis spectroscopy, ESI-mass spectrometry analysis and DFT calculations were conducted. The detection limit of <B>1</B> for Ni<SUP>2+</SUP> was down to nanomolar concentration (57nM). Also, the sensing ability of <B>1</B> for Ni<SUP>2+</SUP> was successfully carried out in real water samples (tap, drinking and sewage water). Moreover, the resulting <B>1</B>-Ni<SUP>2+</SUP> complex acted as an efficient colorimetric chemosensor for CN<SUP>−</SUP> via a color change from yellow to colorless. Therefore, chemosensor <B>1</B> can be employed as a practical colorimetric chemosensor for detecting of both Ni<SUP>2+</SUP> and CN<SUP>−</SUP>.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A novel colorimetric chemosensor 1 for sequential detection of Ni<SUP>2+</SUP> and CN<SUP>−</SUP> was developed. </LI> <LI> Detection limit of <B>1</B> for Ni<SUP>2+</SUP> was down to nanomolar concentration (57nM). </LI> <LI> Sensing ability of <B>1</B> for Ni<SUP>2+</SUP> was successfully carried out in real water samples and visible test strips. </LI> <LI> The resulting <B>1</B>-Ni<SUP>2+</SUP> complex acted as an efficient colorimetric chemosensor for CN<SUP>−</SUP>. </LI> </UL> </P>